Heparin functionalized polyaspartamide/polyester scaffold for potential blood vessel regeneration

Journal of Biomedical Materials Research - Part A

Volumn 102, Issue 5, 2014, Pages 1334-1341

  Pitarresi, Giovanna ^a,b   Fiorica, Calogero ^a   Palumbo, Fabio Salvatore ^a   Rigogliuso, Salvatrice ^a   Ghersi, Giulio ^a   Giammona, Gaetano ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

^c CNR   (Italy)

Author keywords

electrospinning; graft copolymer; heparin; tissue engineering; vascular graft

Indexed keywords

BIOMATERIALS; BLOOD VESSELS; ELECTROSPINNING; GRAFT COPOLYMERS; GRAFTS; POLYCAPROLACTONE; POLYSACCHARIDES; TISSUE ENGINEERING;

BASIC FIBROBLAST GROWTH FACTOR; ELECTROSPUN FIBERS; HEPARIN; HUMAN VASCULAR ENDOTHELIAL CELLS; POLYASPARTAMIDES; SCAFFOLD DEGRADATION; SYNTHETIC VASCULAR GRAFT; VASCULAR GRAFTS;

SCAFFOLDS (BIOLOGY);

ALPHA,BETA POLY(N 2 HYDROXYETHYL)(2 AMINOETHYLCARBAMATE) DEXTRO,LEVO ASPARTAMIDE GRAFT POLYLACTIC ACID; COPOLYMER; FIBROBLAST GROWTH FACTOR 2; HEPARIN; POLYCAPROLACTONE; UNCLASSIFIED DRUG; ALPHA,BETA-POLY(N-2-HYDROXYETHYL)(2-AMINOETHYLCARBAMATE)-D,L-ASPARTAMIDE; ASPARTAME; LACTIC ACID; POLYAMINE; POLYESTER; POLYLACTIC ACID; POLYMER;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL; BLOOD VESSEL GRAFT; CELL PROLIFERATION; CHEMICAL STRUCTURE; COLORIMETRY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ELECTROSPINNING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN INTERACTION; PROTON NUCLEAR MAGNETIC RESONANCE; TISSUE ENGINEERING; ANALOGS AND DERIVATIVES; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; METABOLISM; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSIOLOGY; REGENERATION; SYNTHESIS; TISSUE SCAFFOLD; ULTRASTRUCTURE;

ASPARTAME; BLOOD VESSELS; CELL PROLIFERATION; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; HEPARIN; HUMANS; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR WEIGHT; POLYAMINES; POLYESTERS; POLYMERS; REGENERATION; TISSUE SCAFFOLDS;

EID: 84897114752     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34818     Document Type: Article

References (19)

1. Guyton RA,. Coronary artery bypass is superior to drug-eluting stents in multivessel coronary artery disease. Ann Thorac Surg 2006; 81: 1949-1957.
2. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG,. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45: S5-S67. (Pubitemid 46151680)
3. Chlupáč J, Filová E, Bačáková l,. Blood vessel replacement: 50 years of development and tissue engineering paradigms in vascular surgery. Physiol Res 2009; 58: S119-S139.
4. Haruguchi H, Teraoka S,. Intimal hyperplasia and hemodynamic factors in arterial bypass and arteriovenous grafts: A review. Artif Organs 2003; 6: 227-235. (Pubitemid 38031314)
5. Sarkar S, Salacinski HJ, Hamilton G, Seifalian AM,. The mechanical properties of infrainguinal vascular bypass grafts: Their role in influencing patency. Eur J Vasc Endovasc Surg 2006; 31: 627-636. (Pubitemid 43792949)
6. Zilla PP, Greisler HP, editors. Tissue Engineering of Vascular Prosthetic Grafts. Austin, TX: RG Landes; 1999.
7. Langer R, Vacanti JP,. Tissue engineering. Science 1993; 260: 920-926. (Pubitemid 23209960)
8. Pitarresi G, Palumbo FS, Fiorica C, Calascibetta F, Giammona G,. Electrospinning of α,β-poly(N-2-hydroxyethyl)- dl -aspartamide-graft-polylactic acid to produce a fibrillar scaffold. Eur Polym J 2010; 46: 181-184.
9. Pitarresi G, Fiorica C, Palumbo F S, Calascibetta F, Giammona G,. Polyaspartamide-polylactide electrospun scaffolds for potential topical release of ibuprofen. J Biomed Mater Res A 2012; 6: 1565-1572.
10. Nottelet B, Pektok E, Mandracchia D, Tille JC, Walpoth B, Gurny R, Möller M,. Factorial design optimization and in vivo feasibility of poly(epsilon-caprolactone)-micro- and nanofiber-based small diameter vascular grafts. J Biomed Mater Res A 2009; 15: 865-875.
11. Linhardt RJ, Turnbull JE, Wang HM, Loganathan D, Gallagher JT,. Examination of the substrate specificity of heparin and heparan sulfate lyases. Biochemistry 1990; 29: 2611-2617. (Pubitemid 20100860)
12. Jayson G, Gallagher JT,. Heparin oligosaccharides: Inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer 1997; 75: 9-16. (Pubitemid 27007267)
13. Soker S, Goldstaub D, Svahn CM, Vlodavski I, Levi BZ, Neufeld G,. Variation in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF 165 to its receptors. Biochem Biophys Res Commun 1994; 203: 1339-1347.
14. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsbrun M,. Heparin affinity: Purification of a tumor-derived capillary endothelial cell growth factor. Science 1984; 23: 1296-1299. (Pubitemid 14163183)
15. Giammona G, Carlisi B, Palazzo S,. Reaction of α,β-poly(N- hydroxyethyl)- dl -aspartamide with derivatives of carboxylic acids. J Polym Sci Polym Chem 1987; 25: 2813-2818.
16. Licciardi M, Campisi M, Cavallaro G, Cervello M, Azzolina A, Giammona G,. Synthesis and characterization of polyaminoacidic polycations for gene delivery. Biomaterials 2006; 27: 2066-2075. (Pubitemid 41759501)
17. Palumbo FS, Pitarresi G, Mandracchia D, Tripodo G, Giammona G,. New graft copolymers of hyaluronic acid and polylactic acid: Synthesis and characterization. Carbohydr Polym 2006; 66: 379-85. (Pubitemid 44585067)
18. Singh S, Wu BM, Dunn JC,. The enhancement of VEGF-mediated angiogenesis by polycaprolactone scaffolds with surface cross-linked heparin. Biomaterials 2011; 32: 2059-2069.
19. Zilla P, Bezuidenhout D, Human P,. Prosthetic vascular grafts: Wrong models, wrong questions and no healing. Biomaterials 2007; 28: 5009-5027. (Pubitemid 47489794)